anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The MediBeacon Transdermal GFR Measurement System investigational is intended to measure the Glomerular Filtration Rate (GFR) in patients with normal or impaired renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent (MB-102) over time. The device utilized in this study is the Brilliance device. Approximately 1 male and 1 female from each age cohort (18-50 years; 51+ years) and clustered Fitzpatrick Skin Scale groups (I-II \[Light, pale white; white, fair\]; III-IV \[Medium, white to olive; olive, moderate brown\]; and V-VI \[Brown, dark brown; black, very dark brown to black\]) will be recruited, for a total of 12 participants. Participants will have Brilliance device sensors placed on two locations on their skin, which will remain for 48 hours. The sensor location will be prepared through shaving and cleaning (as applicable), placed on the skin via standard single-use adhesive pads, and baseline measurements collected. Participants may undergo activities of daily living while measurements are being collected. Light pressure and other minor perturbations may be applied to the sensors to evaluate the effect on background fluorescence. Adverse events associated with sensor placement (such as skin irritations) will be recorded.
The participants of this study consisted of 25 volunteers among Acibadem Mehmet Ali Aydinlar University students without prior knowledge of basic life support protocol. 11 Participants (44.0%) were male, 14 (56.0%) were female. The participants were informed about the study and signed consent forms before participating the study. After a brief introduction of the serious gaming module, the participants were asked to choose the self-test mode of the serious game module. The participants' number of attempts was not limited. Following serious game based training, the hands-on training module combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator. The simulation sessions were also recorded in order to use these recordings for conventional OSCE (Objective Structured Clinical Examination) performance evaluation. Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings.Spearman's rho correlation test was used for calculating the correlation between serious gaming, hands on training module with including sensor data from the simulator and OSCE scores.
OBJECTIVES: To investigate the safety of administering low-dose aspirin (81 mg) 18 hours after intravenous thrombolytic therapy.
METHODS: This is a retrospective cohort investigation. Individuals received either alteplase or tenecteplase for acute ischemic stroke followed by aspirin 81 mg (after follow-up imaging). An institutional change moved follow-up post-thrombolytic CT scans to 18 hours, and qualifying patients were grouped based on whether they received aspirin ≤24 hours or >24 hours. Chart reviews were conducted to assess the primary outcome of new or worsening intracranial hemorrhage, as well as secondary outcomes of change in stroke scale scores at discharge and 3 months, lengths of stay, favorable outcomes at 3 months, hospital readmission, and mortality.
RESULTS: Out of 350 patients screened, 130 qualified for inclusion-50 of whom received aspirin ≤24 hours (mean 21.1 hours, SD±6.2), and 80 who received aspirin >24 hours (mean 34 hours, SD±8.2). Only 1 new intracranial bleed occurred following aspirin administration in the >24-hour group. No statistically significant differences were observed in any of the secondary outcomes, although there was higher mortality (3/50 vs. 2/80, P =0.372) and shorter hospital length of stay (median difference -1.0 day, P =0.0336) in the <24 hours group.
CONCLUSIONS: Low-dose aspirin administration sooner than 24 hours following thrombolytic therapy did not increase bleeding events. Sooner aspirin administration after ischemic stroke can potentially enhance the prevention of secondary embolization and did not demonstrate worse clinical outcomes; however, further randomized controlled trials are needed.
More than 525 000 children die each year due to diarrheal disease, the second leading cause of death among children under five. Children from Asian countries, including Vietnamese children, frequently have lactose intolerance. In addition, gastroenteritis, specifically rotavirus-induced gastroenteritis, temporarily impairs lactase enzymes in the intestines. In a recent Cochrane review of 33 randomized and quasi-randomized trials, lactose-free diets reduced diarrhea among children younger than 5 years old. These trials, however, involved inpatients in middle-or high-income countries. Neither patient was from a developing country, where diarrheal diseases often cause significant morbidity and mortality. The purpose of this study is to determine whether lactose-free milk will change the duration and severity of diarrhea in Vietnamese infants with acute gastroenteritis.
Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
BACKGROUND: Mortality for pelvic fracture patients presenting with hemorrhagic shock ranges from 21% to 57%. The objective of this study was to develop a lethal and clinically relevant pelvic hemorrhage animal model with and without bony fracture for evaluating therapeutic interventions. ResQFoam is a self-expanding foam that has previously been described to significantly decrease mortality in large-animal models of abdominal exsanguination. We hypothesized that administration of ResQFoam into the preperitoneal space could decrease mortality in exsanguinating pelvic hemorrhage.
METHODS: Two pelvic hemorrhage models were developed using noncoagulopathic swine. Pelvic hemorrhage model 1: bilateral, closed-cavity, major vascular retroperitoneal hemorrhage without bony pelvic fracture. After injury, animals received no treatment (control, n = 10), underwent preperitoneal packing using laparotomy pads (n = 11), or received ResQFoam (n = 10) injected into the preperitoneal space. Pelvic hemorrhage model 2: unilateral, closed-cavity, retroperitoneal hemorrhage injury (with intraperitoneal communication) combined with complex pelvic fracture. After injury, animals received resuscitation (control, n = 12), resuscitation with preperitoneal packing (n = 10) or with ResQFoam injection (n = 10) into the preperitoneal space.
RESULTS: For model 1, only ResQFoam provided a significant survival benefit. The median survival times were 50 minutes and 67 minutes for preperitoneal packing and ResQFoam, compared with 6 minutes with controls ( p = 0.002 and 0.057, respectively). Foam treatment facilitated hemodynamic stabilization and resulted in significantly less hemorrhage (21.5 ± 5.3 g/kg) relative to controls (31.6 ± 5.0 g/kg, p < 0.001) and preperitoneal packing (32.7 ± 5.4 g/kg, p < 0.001). For model 2, both ResQFoam and preperitoneal packing resulted in significant survival benefit compared with controls. The median survival times were 119 minutes and 124 minutes for the preperitoneal packing and ResQFoam groups, compared with 4 minutes with controls ( p = 0.004 and 0.013, respectively).
CONCLUSION: Percutaneous injection of ResQFoam into the preperitoneal space improved survival relative to controls, and similar survival benefit was achieved compared with standard preperitoneal pelvic packing. The technology has potential to augment the armamentarium of tools to treat pelvic hemorrhage.
Participants in the intervention group received the digtal multi-domain cognitive intervention. The digital multi-domain cognitive intervention system is used to carry out various intervention activities. The activities include learning about health knowledge once a week; home-based exercise three times per week, for 30 minutes each time; art therapy once a week, for 90 minutes at a time; and cognitive training, which includes memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.
The invention relates to a captopril-carrying nano-grade fiber sustained-release system and a preparation method thereof. The sustained-release system comprises the components of: a biodegradable high-molecular material and captopril. The drug-loading rate of the system is 8-80wt%, and the diameter of the nano-grade fiber is 80nm-1.20mum. The preparation method comprises the steps that: (1) the biodegradable high-molecular material is dissolved in an organic solvent; the mixture is stirred until the material is completely dissolved; captopril is added and the mixture is stirred; the mixture is subjected to ultrasonic deaeration, such that a spinning liquid is obtained; (2) the spinning liquid is added into an injector, and electrostatic spinning is carried out, such that the captopril-carrying nano-grade fiber sustained-release system is obtained. According to the invention, with the nano-grade sustained-release system composed of the drug-carrying nano-grade fiber, drug release is effectively controlled. The biodegradable high-molecular material can be automatically degraded with human metabolism, such that an effect of sustained-release is achieved. The process is simple, an equipment cost is low, the conditions are easy to control, and drug availability is improved.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to endocrinology and physiotherapy, and can be used in the treatment of diabetic angiopathy of the lower extremities in patients with type 2 diabetes mellitus. Perform a general impact on the patient's body with a magnetic field with a frequency of 100 Hz, the changing direction of the magnetic field from the patient's head to the legs and the reverse. Value of magnetic induction is 70 % of the maximum value of 3.5 mT. Duration of exposure is 20 minutes. One hour after the magnetotherapy procedure, a thin layer application of therapeutic mud with active humic acids is applied to the lower extremities from the feet to the knees. Temperature of mud is 22–24 °C, an exposition is 30 minutes. Frequency of combined procedures is 4–5 times a week, a course of 10 procedures.EFFECT: method provides an increase in the effectiveness of treatment of patients with type 2 diabetes mellitus, contributing to the reduction of the progression of vascular complications due to the restoration of impaired microcirculation, carbohydrate and fat metabolism, reducing edema of tissues and enhancing reparative processes, reducing the risk of purulent-necrotic complications.1 cl, 2 ex
Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. 

If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Patients with moderate to severe LVEF impairment have not been studied in clinical trials with ELEVIDYS. 

Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion [see Dosage and Administration (2.4)]. Continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. 

Advise patients to contact a physician immediately if they experience cardiac symptoms.
Patients in the intervention group CAG exit Written informed consent was obtained from the patients for the study. Pretest data of the patients were collected at 0 hour using the "Patient Information Form", "Visual Analog Scale", "State Anxiety Scale" and "Immobility Comfort Scale". After informing the patient with hemodynamics, at the 0th hour, a 36x33x10 cm gel-containing silicone pad was placed in the lumbar cavity of the patient to fill the patient's anatomical lumbar cavity, and CAG output was supported. The patient was in the supine position 30 degrees elevated when measured with the visual aid. Patients lie in the same position for 4 hours. Back pain of the patients was evaluated again with the "Visual Analog Scale" at the 2nd hour. At the 4th hour, the posttest data of the patients were collected with the "Visual Analogue Scale", the "State Anxiety Scale" and the "Immobility Comfort Scale".
The goal of this study will be to examine the implementation and preliminary efficacy of a teacher taught gross motor skill-based physical activity (PA) intervention on cognition in low low socio-economic (SES) preschoolers. Low SES preschool centers (n=4) will be recruited and randomly assigned to either a Movement and Cognition (MAC) or a control group. From each preschool center, preschool-age children will be recruited to participate in their assigned center intervention. The MAC intervention will be implemented for 4 days per week for 6 months. The research team will train the preschool providers to implement the intervention. The control centers will be asked to maintain their usual preschool schedule. Primary outcome variables will be processed evaluation data \[study fidelity (adherence, compliance, and integrity of study design), intervention dosage, acceptability, quality, adaptation\], and will be assessed throughout the 6-month study. Secondary outcome variables will be changes in children's cognitive function (executive functions and memory), gross motor skills, and PA levels at baseline, 3- and 6-month. Aim 1 will examine the implementation of a 6-month teacher taught gross motor skill-based movement intervention in low SES preschoolers. Aim 2 will examine the preliminary efficacy of the MAC intervention on cognition, gross motor skills, and PA in preschoolers. For aim 2, the study will compare the outcome variables of interest between the MAC and the control group.
Majority of dental treatments can be performed under local anesthesia. However, this is not always possible for pediatric non-cooperated patients with severe anxiety. In these patients, unpleasant dental experiences may lead to development of dental phobia when they become adults . Therefore, it is important to eradicate anxiety, and to prevent a possible psychological trauma in pediatric patients. For this purpose, psychological and medical methods have been applied to increase patient compliance. It has been proven that general anesthesia especially prevents dental phobia in elderly, and increases the quality of life related to oral health. In this study we aimed to evaluated the patients in whom dental local anesthetic attempts were failed due to anxiety or fear and referred to our clinic for tooth extraction with deep sedation. All patients dates will evaluate from their patient file retrospectively from 2011 to 2014.
This invention teaches systems and methods for identifying, targeting and destroying cancer cells with a cell-killing vector attracted to signature elements common to most cancer cells. As cells progress from a normal to a cancerous state their accelerated metabolic rates and adapted pathways generate excess amounts of H +  (resulting in a locally reduced pH) along with a higher heat signature that can serve as a targeting beacon for a specialized cell killing vectors such as a virus and/or a liposome. The cancer cell's heat/pH signature in large part is due to the cell's decreased reliance on mitochondria and the mitochondrial electron transport chain. A lactate overload built up using the alternative ATP generation pathway must be excreted by the cell. Co-transport of H + /lactate is accomplished mainly through a mono-carboxylate transporter 4 protein (MCT4). The present invention while using the pH/heat signature as a delivery adjunct increases targeted killing effectiveness by improving the cell killer vector targeting with a protein capable of binding MCT4. The higher concentration of vector in contact with the targeted cells enhances the heat and pH associated delivery of lethal agents.
Neuropsychiatric consequences of brain ischemia play a critical role in shaping long-term stroke outcome. Unfortunately, however, as of now, clinical research and clinical practice have not adequately addressed this growing challenge. A good case in point is posttraumatic stress disorder (PTSD). Previous trauma exposure and posttraumatic stress symptoms may increase the risk of cardiovascular events (Sumner et al., 2015). Moreover, unbeknownst to most clinical neurologists, a significant portion (approximately 25%) of their stroke patients develop symptoms of post-traumatic stress disorder (PTSD) within the first year post-event. PTSD-related symptoms after an acute coronary syndrome increase the risk of recurrent cardiac events and mortality (Edmondson et al., 2012). Similarly, stroke-induced PTSD has been linked with worse long term stroke outcome, in particular, recurrent stroke, greater disability, non-adherence to medications, and comorbidities (Goldfinger et al., 2014; Kronish et al., 2012).

For a period of 22 months, all stroke patients treated at the Charité Medical Center will be screened retrospectively 9-13 months after a first-ever ischemic stroke (\~2000). All eligible patients will be contacted by mail 9-13 months after their hospital stay with the request that they complete the questionnaires. The mailing will also include an information statement, the consent form, as well as a stamped return envelope.
The significant impact of acute respiratory tract infections on healthcare systems is well-documented, given their contribution to emergency department admissions, hospitalizations, and increased use of antibiotics and other medications. However, further research is needed to understand the burden of acute respiratory tract infections in pediatric community care to develop effective public health interventions and improve child health outcomes. Real-world data were retrieved from Pedianet, an Italian network of over 200 family pediatricians. Acute respiratory tract infection visits were identified and analysed using an infection-duration algorithm to extract individual cases. The number of follow-up visits per 100 cases was calculated to assess the burden on the Italian National Health Service. Comparisons were made overall and stratified by type of acute respiratory tract infections and epidemiological season. A total of 1,402,953 acute respiratory infections-related visits were recorded, with an overall rate of 12 visits per 100 cases. Upper respiratory tract infections had an average of 9 visits per 100 cases. Lower respiratory tract infections exhibited a higher burden, with 29 visits per 100 cases. Pneumonia showed a declining trend in the pre-pandemic era (62 to 48 visits) but rebounded in the post-COVID-19 years (32 to 42 visits). This study underscores the importance of monitoring and managing acute respiratory infections, especially lower respiratory tract infections, in pediatric care.
Patients who enrolled will receive one dose of CMV-TCR-T cells. The dosage ranges from 0.3×10\^6 to 1×10\^7 TCR+T/Kg.
Participants with receive BNI, Referral to Treatment, and MAUD. In the MAUD component, either XR-NTX or oral naltrexone will be provided, supplemented by ancillary treatment with gabapentin. Participants will receive their first doses of XR-NTX (injection) and gabapentin in the ED and will receive 7 days of gabapentin take-home doses. Those who prefer to initiate treatment in ED with oral naltrexone receive their first doses of naltrexone and gabapentin in the ED and receive 29-day take-home doses of naltrexone and 7 days of gabapentin.
Participants tissue will be incubated in plasma rich in growth factors prior to endothelial keratoplasty procedure. Participants will be followed up for up to 1 year.
The invention discloses a dracaena cambodiana leaf ultramicro pure powder, a preparation method therefor, and preparations thereof. The dracaena cambodiana leaf ultramicro pure powder is prepared from fresh dracaena cambodiana leaves and obtained after pretreatment, desiccation, coarse grinding, superfine grinding, packaging and sterilization. The preparation method for the dracaena cambodiana leaf ultramicro pure powder comprises steps of pretreatment, desiccation, coarse grinding, superfine grinding packaging and sterilization, and concretely comprises steps: impurities are removed from the dracaena cambodiana leaves, the dracaena cambodiana leaves are selected, cleaned, sliced, dried in the sun, desiccated, crushed and sieved through a 10-mesh sieve, the crushed materials are subjected to superfine grinding to obtain target objects, the target objects are disinfected and inspected, and inspection reports are provided. The preparations comprise powders, granules and tablets. The dracaena cambodiana leaf ultramicro pure powder is prepared from nuisanceless dracaena cambodiana leaves. Medicinal active ingredients of dracaena cambodiana leaves are retained to the extreme in process of preparation. Waste of dracaena cambodiana leaf resource is reduced. The bioavailability of dracaena cambodiana leaves is raised. Dracaena cambodiana leaves are utilized efficiently.
The present invention discloses a preparation method of multi-target miRNA antisense nucleotide, relating to an antisense nucleotide technology. The present invention is capable to solve the problems of existing method for silencing miRNAs, e.g. single target and poor action efficacy. The preparation method of multi-target miRNA antisense nucleotide is achieved by the following procedures: 1. miRNA that capable to regulate the key gene (i.e. pathogenic gene) is found through gene chip screening or provision of documentation; 2. a plurality of antisense miRNA antisense nucleotides are designed into a single-nucleotide sequence that can silence a plurality of multi-target miRNAs, i.e. the preparation method of multi-target miRNA antisense nucleotide is achieved. The present invention can be used as a simple and direct method to conduct study on the bioprocess containing various miRNAs and genes. Compared with existing methods, the greatest advantage of CAMO method lies in that one drug molecule is capable to regulate multi-target genes and the action efficacy is stronger. The preparation method of multi-target miRNA antisense nucleotide provided by the present invention can well settle the problems of existing methods, i.e. single target and poor action efficacy.
Stable aqueous solutions of oxytetracycline, suitable for parenteral, peroral and local (e.g. intramammary) administration, are prepared by mixing together in a aqueous medium oxytetracycline either as a salt or base, polyvinylpyrrolidone and a magnesium compound ionizable in the medium to provide magnesium ions and adjusting the pH of the mixture to a value from 8.0 to 9.5. The magnesium compound may be a magnesium salt, e.g. chloride or sulphate, or magnesium oxide. The polyvinyl pyrrolidone may have an average mol. wt. from 10,000 to 60,000 and have a concentration in the final solution from 7.5 to 25% by weight. The solutions may also contain reducing substances such as sodium metabisulphite, sodium sulphite, or sodium formaldehyde sulphoxylate.